2005 AES annual course: evidence used to treat women with epilepsy (Q36625015)

15 August 2017

1 reference

title

2005 AES annual course: evidence used to treat women with epilepsy (English)

1 reference

15 August 2017

Page B Pennell

1

1 reference

15 August 2017

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

47 Suppl 1

1 reference

15 August 2017

46-53

1 reference

Three patterns of catamenial epilepsy

15 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Frequency of catamenial seizure exacerbation in women with localization-related epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Progesterone therapy in women with complex partial and secondary generalized seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Folic acid antagonists during pregnancy and the risk of birth defects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Population based, prospective study of the care of women with epilepsy in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

The teratogenicity of anticonvulsant drugs: a progress report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Early puberty: what is normal and when is treatment indicated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Increased rate of major malformations in offspring exposed to valproate during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

In utero antiepileptic drug exposure: fetal death and malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Maternal valproate dosage and foetal malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Antiepileptic drug pharmacokinetics during pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

The impact of pregnancy and childbirth on the metabolism of lamotrigine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Individual changes in lamotrigine plasma concentrations during pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Oral contraceptives reduce lamotrigine plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Additional educational needs in children born to mothers with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Normal intelligence in children with prenatal exposure to carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

The longer term outcome of children born to mothers with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Neuropsychological effects of exposure to anticonvulsant medication in utero

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Drug therapy for breast-feeding women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Acetaminophen toxicity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

Levetiracetam concentrations in serum and in breast milk at birth and during lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00660.X

10.1111/J.1528-1167.2006.00660.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17044826